Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
latency-reversing
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "latency-reversing" in MCE Product Catalog:
Cat. No.: HY-119490
CAS No.: 2109805-83-4
Target:
Research Areas:
UMB-136 is a bromodomain inhibitor. UMB-136 is a promising latency-reversing agent (LRA) for HIV-1 eradication. UMB-136 reactivates HIV-1 in multiple cell models. UMB-136 enhances HIV-1 transcription and increases viral production through the release of P-TEFb .
Cat. No.: HY-147553
CAS No.: 2170506-18-8
HIV-1 inhibitor-36 (Compound 2) is a potent HIV-1. HIV-1 inhibitor-36 has the potential for further development as novel latency reversing agents .
Cat. No.: HY-147554
CAS No.: 2416971-40-7
HIV-1 inhibitor-37 (Compound 83) is a potent HIV-1. HIV-1 inhibitor-37 has the potential for further development as novel latency reversing agents .
Cat. No.: HY-147555
CAS No.: 2416971-48-5
HIV-1 inhibitor-38 (Compound 91) is a potent HIV-1. HIV-1 inhibitor-38 has the potential for further development as novel latency reversing agents .
Cat. No.: HY-155599
CAS No.: 2982527-11-5
HIV-1 protease-IN-10 (Compound 2) has HIV-1 latency reversing activity (IC50: 0.22 μM). HIV-1 protease-IN-10 binds to the PKCδ C1b domain (IC50: 0.69 μM). HIV-1 protease-IN-10 has stability against esterase-mediated hydrolysis .
Cat. No.: HY-147552
CAS No.: 2416971-32-7
HIV-1 inhibitor-35 (compound 74) is a potent HIV-1 inhibitor with EC50s of 80 nM and 70 nM for LTR and CMV in HEK293 cells, respectively. HIV-1 inhibitor-35 has inhibitory activity against liver cancer cell HepG2 with a CC50 of 40 nM. HIV-1 inhibitor-35 can be used as HIV-1 latency reversing agent .
Cat. No.: HY-181164
Target:
Research Areas:
PROTAC BRD4 Degrader-43 is a BRD4 PROTAC degrader. PROTAC BRD4 Degrader-43 recruits the DCAF1-DDB1-Cul4A E3 ligase complex via a Vpr-derived peptide moiety to induce BRD4 ubiquitination and degradation through the ubiquitin-proteasome system. PROTAC BRD4 Degrader-43 exhibits potent HIV latency-reversing activity. PROTAC BRD4 Degrader-43 can be used for the research of HIV-1 latent infection . (Pink: BRD4 ligand (HY-13030); Blue: Cul4A-DDB1-DCAF1 ligand (HY-P11640); Black: conjugate of PEG linker + cell-penetrating peptide (HY-P2483))
Cat. No.: HY-181831
Research Areas:
XQ2 is a resveratrol (HY-16561) derivative and latency-reversing agent. XQ2 releases positive transcription elongation factor b (P-TEFb) from BRD4, thereby promoting Tat-dependent viral transcription. XQ2 reactivates latent HIV-1 via activating P-TEFb .
Cat. No.: HY-134844
CAS No.: 2433895-70-4
Synonyms: SBI-0953294
Ciapavir (SBI-0953294) is a HIV-1 latency-reversing agent. Ciapavir reverses latent HIV-1 reservoir in vitro and in vivo without inducing systemic T cell activation or broad cytokine release. Ciapavir degrades cIAP1 and activates non-canonical NF-κB pathway. Ciapavir can be used for the research of HIV-1 infection .
Cat. No.: HY-181841
CAS No.: 2796210-93-8
Target:
Research Areas:
TLR8 agonist 10 is a selective TLR8 agonist with an EC50 of 0.019 μM in humans. TLR8 agonist 10 activates TLR8-mediated signaling pathways. As a latency-reversing agent, TLR8 agonist 10 reactivates latent HIV-1 reservoirs. TLR8 agonist 10 activates innate cytotoxic natural killer cells to target HIV-infected CD4 + T cells. TLR8 agonist 10 is applicable to research related to HIV-1 infection .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
